ADSL and urinary tract infection: The second trial on urinary tract infection provided insights into the effects of estrogen treatment on pelvic floor microbiome (PFM) diversity, female urinary microbiota (FUM), antimicrobial peptide (AMPs) levels, and OAB symptoms in hypoestrogenic women.